IMV IMV Inc.

2.83
-0.02  -1%
Previous Close 2.85
Open 3
Price To Book 12.86
Market Cap 143,285,376
Shares 50,630,875
Volume 15,767
Short Ratio
Av. Daily Volume 7,750
Stock charts supplied by TradingView

NewsSee all news

  1. IMV to Participate at Two Upcoming Investor Conferences

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV's executive management team will

  2. IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Reported preliminary data from Phase 2 basket study of DPX-Survivac in multiple solid tumors at the ESMO annual meeting, showing treatment was well-tolerated and showed signs of clinical activity Entered into

  3. Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage biopharmaceutical company

  4. IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting

    Robust survivin-specific T cell responses observed in recurrent late-stage ovarian cancer in nearly all evaluable subjects Survivin-specific T cells remain active and proliferative over time, leading to T cell

  5. IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Joanne Schindler, M.D., D.V.M. as its new Chief Medical Officer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 presentation at ASH December 8, 2019 at 6pm. Top-line data due 1H 2020.
DPX-Survivac and pembrolizumab
Diffuse Large Cell Lymphoma
Phase 2 top-line data due 1Q 2020.
DPX-Survivac and epacadostat (DeCidE1)
Ovarian cancer
Phase 2 trial ongoing.
DPX-Survivac and pembrolizumab
Ovarian cancer
Phase 2 top-line data due 1H 2020.
DPX-Survivac and KEYTRUDA (pembrolizumab) - basket trial
Solid tumors
Phase 1 dosing has commenced - January 17, 2019.
DPX-NEO - neoepitopes
Ovarian cancer

Latest News

  1. IMV to Participate at Two Upcoming Investor Conferences

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV's executive management team will

  2. IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Reported preliminary data from Phase 2 basket study of DPX-Survivac in multiple solid tumors at the ESMO annual meeting, showing treatment was well-tolerated and showed signs of clinical activity Entered into

  3. Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage biopharmaceutical company

  4. IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting

    Robust survivin-specific T cell responses observed in recurrent late-stage ovarian cancer in nearly all evaluable subjects Survivin-specific T cells remain active and proliferative over time, leading to T cell

  5. IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Joanne Schindler, M.D., D.V.M. as its new Chief Medical Officer,

  6. IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on

  7. IMV Inc. to Present at Upcoming Investor Conference

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage immuno-oncology company, today announced that company management will be attending the BIO Investor Forum to be held on October 22-23 at the Westin St. Francis, San

  8. Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

    Tumor regressions and partial responses observed in subjects with ovarian, non-small cell lung and bladder cancer Treatment well-tolerated, with no related Grade 3-4 or immune-related adverse events IMV Inc.

  9. Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage immuno-oncology company, today announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck's Keytruda®

  10. IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis

  11. IMV Inc. to Present at Upcoming Investor Conferences

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage immuno-oncology company, today announced that company management will be presenting at the following investor conferences in September: Wells Fargo 14th Annual